Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $23.89.

Several brokerages recently weighed in on KURA. Barclays reduced their price target on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. UBS Group decreased their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research note on Tuesday, April 29th. Finally, BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC grew its stake in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares during the period. Pallas Capital Advisors LLC purchased a new stake in Kura Oncology in the first quarter worth approximately $66,000. Flower City Capital purchased a new stake in Kura Oncology during the 1st quarter valued at $79,000. Harbor Advisors LLC bought a new position in shares of Kura Oncology during the 4th quarter valued at $87,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Kura Oncology during the fourth quarter valued at $90,000.

Kura Oncology Trading Up 6.4 %

NASDAQ:KURA opened at $6.00 on Friday. The company has a 50-day moving average price of $6.60 and a 200-day moving average price of $9.31. The stock has a market cap of $519.45 million, a price-to-earnings ratio of -2.54 and a beta of 0.50. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. Equities analysts predict that Kura Oncology will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.